275 related articles for article (PubMed ID: 24590173)
1. CIP2A oncoprotein controls cell growth and autophagy through mTORC1 activation.
Puustinen P; Rytter A; Mortensen M; Kohonen P; Moreira JM; Jäättelä M
J Cell Biol; 2014 Mar; 204(5):713-27. PubMed ID: 24590173
[TBL] [Abstract][Full Text] [Related]
2. KIAA1524/CIP2A promotes cancer growth by coordinating the activities of MTORC1 and MYC.
Puustinen P; Jäättelä M
Autophagy; 2014 Jul; 10(7):1352-4. PubMed ID: 24905455
[TBL] [Abstract][Full Text] [Related]
3. CIP2A signature reveals the MYC dependency of CIP2A-regulated phenotypes and its clinical association with breast cancer subtypes.
Niemelä M; Kauko O; Sihto H; Mpindi JP; Nicorici D; Pernilä P; Kallioniemi OP; Joensuu H; Hautaniemi S; Westermarck J
Oncogene; 2012 Sep; 31(39):4266-78. PubMed ID: 22249265
[TBL] [Abstract][Full Text] [Related]
4. Cucurbitacin B induces autophagy and apoptosis by suppressing CIP2A/PP2A/mTORC1 signaling axis in human cisplatin resistant gastric cancer cells.
Liu X; Duan C; Ji J; Zhang T; Yuan X; Zhang Y; Ma W; Yang J; Yang L; Jiang Z; Yu H; Liu Y
Oncol Rep; 2017 Jul; 38(1):271-278. PubMed ID: 28534965
[TBL] [Abstract][Full Text] [Related]
5. CIP2A regulates cell proliferation via the AKT signaling pathway in human lung cancer.
Lei N; Peng B; Zhang JY
Oncol Rep; 2014 Oct; 32(4):1689-94. PubMed ID: 25109354
[TBL] [Abstract][Full Text] [Related]
6. CIP2A inhibits PP2A in human malignancies.
Junttila MR; Puustinen P; Niemelä M; Ahola R; Arnold H; Böttzauw T; Ala-aho R; Nielsen C; Ivaska J; Taya Y; Lu SL; Lin S; Chan EK; Wang XJ; Grènman R; Kast J; Kallunki T; Sears R; Kähäri VM; Westermarck J
Cell; 2007 Jul; 130(1):51-62. PubMed ID: 17632056
[TBL] [Abstract][Full Text] [Related]
7. Cancerous inhibitor of protein phosphatase 2A, an emerging human oncoprotein and a potential cancer therapy target.
Khanna A; Pimanda JE; Westermarck J
Cancer Res; 2013 Nov; 73(22):6548-53. PubMed ID: 24204027
[TBL] [Abstract][Full Text] [Related]
8. Tamoxifen induces apoptosis through cancerous inhibitor of protein phosphatase 2A-dependent phospho-Akt inactivation in estrogen receptor-negative human breast cancer cells.
Liu CY; Hung MH; Wang DS; Chu PY; Su JC; Teng TH; Huang CT; Chao TT; Wang CY; Shiau CW; Tseng LM; Chen KF
Breast Cancer Res; 2014 Sep; 16(5):431. PubMed ID: 25228280
[TBL] [Abstract][Full Text] [Related]
9. CIP2A silencing alleviates doxorubicin resistance in MCF7/ADR cells through activating PP2A and autophagy.
Zhu Z; Wei Z
Clin Transl Oncol; 2021 Aug; 23(8):1542-1548. PubMed ID: 33948919
[TBL] [Abstract][Full Text] [Related]
10. FL118 inhibits viability and induces apoptosis of colorectal cancer cells via inactivating the CIP2A/PP2A axis.
Lin X; Gao M; Zhang A; Tong J; Zhang X; Su Q; Yang Z; Gao H; Jiang G
Life Sci; 2019 Dec; 239():117074. PubMed ID: 31751585
[TBL] [Abstract][Full Text] [Related]
11. Temsirolimus enhances the efficacy of cetuximab in colon cancer through a CIP2A-dependent mechanism.
Wang HW; Yang SH; Huang GD; Lin JK; Chen WS; Jiang JK; Lan YT; Lin CC; Hwang WL; Tzeng CH; Li AF; Yen CC; Teng HW
J Cancer Res Clin Oncol; 2014 Apr; 140(4):561-71. PubMed ID: 24493623
[TBL] [Abstract][Full Text] [Related]
12. CIP2A is a target of bortezomib in human triple negative breast cancer cells.
Tseng LM; Liu CY; Chang KC; Chu PY; Shiau CW; Chen KF
Breast Cancer Res; 2012 Apr; 14(2):R68. PubMed ID: 22537901
[TBL] [Abstract][Full Text] [Related]
13. Arctigenin inhibits triple-negative breast cancers by targeting CIP2A to reactivate protein phosphatase 2A.
Huang Q; Qin S; Yuan X; Zhang L; Ji J; Liu X; Ma W; Zhang Y; Liu P; Sun Z; Zhang J; Liu Y
Oncol Rep; 2017 Jul; 38(1):598-606. PubMed ID: 28560452
[TBL] [Abstract][Full Text] [Related]
14. CIP2A regulates proliferation and apoptosis of multiple myeloma cells.
Zheng Z; Qiao Z; Chen W; Gong R; Wang Y; Xu L; Ma Y; Zhang L; Lu Y; Jiang B; Li G; Dong C
Mol Med Rep; 2016 Sep; 14(3):2705-9. PubMed ID: 27484817
[TBL] [Abstract][Full Text] [Related]
15. CIP2A influences survival in colon cancer and is critical for maintaining Myc expression.
Wiegering A; Pfann C; Uthe FW; Otto C; Rycak L; Mäder U; Gasser M; Waaga-Gasser AM; Eilers M; Germer CT
PLoS One; 2013; 8(10):e75292. PubMed ID: 24098375
[TBL] [Abstract][Full Text] [Related]
16. Targeting SET to restore PP2A activity disrupts an oncogenic CIP2A-feedforward loop and impairs triple negative breast cancer progression.
Liu CY; Huang TT; Chen YT; Chen JL; Chu PY; Huang CT; Wang WL; Lau KY; Dai MS; Shiau CW; Tseng LM
EBioMedicine; 2019 Feb; 40():263-275. PubMed ID: 30651219
[TBL] [Abstract][Full Text] [Related]
17. Hyperactivation of mammalian target of rapamycin complex 1 (mTORC1) promotes breast cancer progression through enhancing glucose starvation-induced autophagy and Akt signaling.
Chen Y; Wei H; Liu F; Guan JL
J Biol Chem; 2014 Jan; 289(2):1164-73. PubMed ID: 24275666
[TBL] [Abstract][Full Text] [Related]
18. CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells.
Chen KF; Liu CY; Lin YC; Yu HC; Liu TH; Hou DR; Chen PJ; Cheng AL
Oncogene; 2010 Nov; 29(47):6257-66. PubMed ID: 20729919
[TBL] [Abstract][Full Text] [Related]
19. Tumor suppressor miR-375 regulates MYC expression via repression of CIP2A coding sequence through multiple miRNA-mRNA interactions.
Jung HM; Patel RS; Phillips BL; Wang H; Cohen DM; Reinhold WC; Chang LJ; Yang LJ; Chan EK
Mol Biol Cell; 2013 Jun; 24(11):1638-48, S1-7. PubMed ID: 23552692
[TBL] [Abstract][Full Text] [Related]
20. CIP2A facilitates the G1/S cell cycle transition via B-Myb in human papillomavirus 16 oncoprotein E6-expressing cells.
Tian Y; Chen H; Qiao L; Zhang W; Zheng J; Zhao W; Chen JJ; Zhang W
J Cell Mol Med; 2018 Sep; 22(9):4150-4160. PubMed ID: 29893470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
